



BioCorporate profile downloaded from - <http://www.bioportfolio.com> on Friday, November 27, 2009

BioChem Pharma Incorporated

[View the current BioChem Pharma Incorporated Page on BioPortfolio.com](http://www.bioportfolio.com/bioporcorporate/1453-BioChem+Pharma+Incorporated.html)

(<http://www.bioportfolio.com/bioporcorporate/1453-BioChem+Pharma+Incorporated.html>)

Contact Details:

275 Armand-Frappier Boulevard

Laval

Quebec

H7V 4A7

Canada

Tel: 450 681 1744

Fax: 450 978 7755

Email:

BioChem Pharma Inc. (BioChem) is an international biopharmaceutical company dedicated to the research, development and commercialization of innovative products mainly for the prevention and treatment of human diseases, with a focus in cancer and infectious diseases.

Press Releases on BioChem Pharma Incorporated:

["As an Industry,](#)

[We've Been too](#)

[Focused on Regulatory](#)

[Approval," Says Solvay](#)

[Pharmaceuticals Eric](#)

[Rambeaux at the Pharma](#)

[Marketing Summit.](#)

26th November,
2009

LONDON, November 26

/PRNewswire/ -- Rambeaux joined a host of other industry leaders at eyeforpharma's 9th annual Pharma Marketing Summit 2009 conference in Berlin, where several key themes

[Cytochroma to Present at](#)

[21st Annual Piper Jaffray](#)

[Health Care Conference](#)

25th November,
2009

Cytochroma

MARKHAM, ON, Nov. 25

/PRNewswire/ - Cytochroma today announced that Charles W. Bishop, PhD, President and CEO, will be presenting a corporate overview at the 21st Annual Piper Jaffray Health Care

[Cytochroma Announces](#)

[Appointment of Peter](#)

[Moldt to Board of](#)

[Directors](#)

25th November,
2009

Cytochroma

MARKHAM, ON, Nov. 25

/PRNewswire/ - Cytochroma today announced the appointment of Peter Moldt, PhD to its Board of Directors. Dr. Moldt will replace Mr. Ulrik Spork as the Novo A/S representative on

[Reportlinker Adds](#)

[Intranasal Drug Delivery -](#)

[US Market Trends &](#)

[Analysis](#)

25th November,
2009

Reportlinker

NEW YORK, Nov. 25 /PRNewswire/
-- Reportlinker.com announces that
a new market research report is
available in its catalogue: *Intranasal
Drug Delivery - US Market Trends &
Analysis* <http://www>

[Reportlinker Adds](#)

[Regenerative Medicine -](#)

[Global Market Trends](#)

25th November,
2009

Reportlinker

NEW YORK, Nov. 25 /PRNewswire/
-- Reportlinker.com announces that
a new market research report is
available in its catalogue:
*Regenerative Medicine - Global
Market Trends*
<http://www.reportlinker.com>

BioNews Results for BioChem Pharma Incorporated



- [Medical News: Sirona Biochem Says New Results From Big Pharma Shows Why SGLT2 Sugar Blockers Are A Major Opportunity In Fighting Diabetes](#)
BioFind: Nov 18 2009 2:10PM Matching: biochem pharma
- [Medical News: Sirona Biochem Says New Results From Big Pharma Shows Why SGLT2 Sugar Blockers Are A Major Opportunity In Fighting Diabetes](#)
BioFind: Nov 18 2009 2:09PM Matching: biochem pharma
- [Sirona Biochem Says New Results From Big Pharma Shows Why SGLT2 Sugar Blockers Are A Major Opportunity In Fighting Diabetes](#)
Medical News Today: Nov 18 2009 9:07PM Matching: biochem pharma
- [Sirona Biochem Says New Results From Big Pharma Shows Why SGLT2 Sugar Blockers Are a Major Opportunity in Fighting Diabetes](#)
Individual.com: Nov 18 2009 4:55AM Matching: biochem pharma
- [Sirona Biochem Says New Results From Big Pharma Shows Why SGLT2 Sugar Blockers Are a Major Opportunity in Figh](#)
Quote.com France: Nov 17 2009 2:34PM Matching: biochem pharma
- [Sirona Biochem Says New Results From Big Pharma Shows Why SGLT2 Sugar Blockers Are a Major Opportunity in Figh](#)
Market Wire: Nov 17 2009 1:21PM Matching: biochem pharma
- [Sirona Biochem Says New Results From Big Pharma Shows Why SGLT2 Sugar Blockers Are a Major Opportunity in Figh](#)
Freshnews.com: Nov 17 2009 1:52PM Matching: biochem pharma
- [GSK teams up with Nabi on NicVax](#)
In-Pharmatechnologist: Nov 17 2009 11:51AM Matching: biochem pharma
- [Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies Of Apoptone \(HE3235\) At](#)
Medical News Today: Nov 17 2009 9:23AM Matching: biochem pharma
- [One of Canada's Leading Biotech Pioneers Joins Sirona Biochem's Scientific Advisory Board](#)
Pharmacy Choice: Nov 16 2009 8:13AM Matching: biochem pharma
- [Gentium Announces New Board of Directors and Interim CEO](#)
Pharma Live: Nov 9 2009 7:27PM Matching: biochem pharma
- [Canada needs two vaccine suppliers, Ottawa admits](#)

Globe and Mail: Nov 6 2009 2:57PM Matching: biochem pharma

- [One of Canada's Leading Biotech Pioneers Joins Sirona Biochem's Scientific Advisory Board](#)

PR-USA.net: Nov 5 2009 12:58PM Matching: biochem pharma

- [Long-term Outcomes Data Validates the Utility of PROSTASCINT in Guiding Targeted Prostate Cancer Treatment and](#)

Pharma Live: Nov 5 2009 9:55AM Matching: biochem pharma

- [EUSA Pharma's PROSTASCINT effective in guiding targeted prostate cancer treatment](#)

News-Medical.Net: Nov 4 2009 1:46PM Matching: biochem pharma

BioChem Pharma Incorporated Patents:



- 5593970- [Heterocyclic anthracycline analogs](#)
- 5955610- [Antiviral compounds](#)
- 5980913- [Peptides having immunomodulatory activity](#)
- 5990104- [Polycyclic alcaloid-derivatives as NMDA-receptor antagonists](#)
- 5994361- [Substituted purinyl derivatives with immunomodulating activity](#)
- 6005107- [Antiviral compounds](#)
- 6054474- [Heterocyclic compounds for the treatment of pain and use thereof](#)
- 6057314- [Low molecular weight bicyclic thrombin inhibitors](#)
- 6069250- [Method and compositions for the synthesis of dioxolane nucleosides with .beta.-configuration](#)
- 6110923- [Method for treating cancer using novel substituted purinyl derivatives with immunomodulating activity](#)
- 6127540- [Antiviral compounds](#)
- 5955493- [Thiamorphinans with neuroprotective activity](#)
- 5922867- [Method and compositions for the synthesis of dioxolane nucleosides with .beta. configuration](#)
- 5763606- [Stereoselective synthesis of nucleoside analogues using bicyclic intermediate](#)
- 5606037- [Processes antineoplastic heteronaphthoquinones](#)
- 5618820- [1,3-oxathiolane nucleoside analogues and methods for using same](#)
- 5663320- [Processes for the diastereoselective separation of nucleoside analogue synthetic intermediates](#)
- 5684164- [Processes for preparing substituted 1,3-oxathiolanes with antiviral properties](#)
- 5688771- [Lipophilic oligopeptides with immunomodulating activity](#)
- 5693787- [Intermediates in the synthesis of 1,3-oxathiolanyl cytosine nucleoside analogues](#)
- 5696254- [Processes for the diastereoselective synthesis of nucleoside analogues](#)
- 5736523- [Antineoplastic heteronaphthoquinones](#)
- 5744596- [Nucleoside analogues and synthetic intermediates](#)
- 5756706- [Processes for the diastereoselective synthesis of nucleoside analogues](#)
- 6156737- [Use of dideoxy nucleoside analogues in the treatment of viral infections](#)
- 6175008- [Processes for preparing substituted 1,3-oxathiolanes with antiviral properties](#)
- 6545001- [Antiviral nucleoside analogues](#)
- 6566365- [Method for the treatment of Flaviviridea viral infection using nucleoside analogues](#)
- 6583149- [Method for the treatment or prevention of viral infection using nucleoside analogues](#)
- 6605614- [\[1,8\] naphthyridine derivatives having antiviral activity](#)
- 6630480- [Methods of treating leukemia](#)

- 6630488- [Quinolizinones as integrin inhibitors](#)
- 6743910- [Stereoselective synthesis of nucleoside analogues](#)
- 6747036- [Methods of treating leukemia](#)
- 6784161- [Method for the treatment or prevention of flavivirus infections using nucleoside analogues](#)
- 6903224- [Substituted 1,3-oxathiolanes](#)
- 6541625- [Stereoselective synthesis of nucleoside analogues](#)
- 6534520- [Antiviral compounds](#)
- 6511983- [Pharmaceutical combination of antiviral agents](#)
- 6180639- [1,3-oxathiolane nucleoside analogues](#)
- 6194576- [Process for preparing antiviral 2-phosponate nucleotide analogs](#)
- 6228860- [Substituted 1,3-oxathiolanes with antiviral properties](#)
- 6255318- [Antiviral compounds](#)
- 6274620- [Thiophene integrin inhibitors](#)
- 6287574- [Proteinase K resistant surface protein of neisseria meningitidis](#)
- 6350753- [2-Substituted-4-substituted-1,3-dioxolanes and use thereof](#)
- 6358963- [Antiviral nucleoside analogues](#)
- 6369066- [Substituted 1,3-oxathiolanes with antiviral properties](#)
- 6444656- [Antiviral phosphonate nucleotides](#)
- 7470666- [Use of Ulinastatin and its pharmaceutical composition for treating severe acute respiratory syndrome](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

